» Articles » PMID: 26991284

Isolation of Recombinant Antibodies Directed Against Surface Proteins of Clostridium Difficile

Overview
Specialty Microbiology
Date 2016 Mar 19
PMID 26991284
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Clostridium difficile has emerged as an increasingly important nosocomial pathogen and the prime causative agent of antibiotic-associated diarrhoea and pseudomembranous colitis in humans. In addition to toxins A and B, immunological studies using antisera from patients infected with C. difficile have shown that a number of other bacterial factors contribute to the pathogenesis, including surface proteins, which are responsible for adhesion, motility and other interactions with the human host. In this study, various clostridial targets, including FliC, FliD and cell wall protein 66, were expressed and purified. Phage antibody display yielded a large panel of specific recombinant antibodies, which were expressed, purified and characterised. Reactions of the recombinant antibodies with their targets were detected by enzyme-linked immunosorbent assay; and Western blotting suggested that linear rather than conformational epitopes were recognised. Binding of the recombinant antibodies to surface-layer proteins and their components showed strain specificity, with good recognition of proteins from C. difficile 630. However, no reaction was observed for strain R20291-a representative of the 027 ribotype. Binding of the recombinant antibodies to C. difficile M120 extracts indicated that a component of a surface-layer protein of this strain might possess immunoglobulin-binding activities. The recombinant antibodies against FliC and FliD proteins were able to inhibit bacterial motility.

Citing Articles

Host Immune Responses to Surface S-Layer Proteins (SLPs) of .

Chandra H, Kovall R, Yadav J, Sun X Microorganisms. 2023; 11(2).

PMID: 36838345 PMC: 9963625. DOI: 10.3390/microorganisms11020380.


Comparative biofilm-forming ability between strains isolated in Latin America and the epidemic NAP1/027 strain.

Morais M, Santos M, Costa C, Martins C, Leitao R, Pacifico D Front Cell Infect Microbiol. 2023; 12:1033698.

PMID: 36619751 PMC: 9815708. DOI: 10.3389/fcimb.2022.1033698.


Rapid-format recombinant antibody-based methods for the diagnosis of infection: Recent advances and perspectives.

Raeisi H, Azimirad M, Aghdaei H, Yadegar A, Zali M Front Microbiol. 2022; 13:1043214.

PMID: 36523835 PMC: 9744969. DOI: 10.3389/fmicb.2022.1043214.


Application of recombinant antibodies for treatment of infection: Current status and future perspective.

Raeisi H, Azimirad M, Nabavi-Rad A, Aghdaei H, Yadegar A, Zali M Front Immunol. 2022; 13:972930.

PMID: 36081500 PMC: 9445313. DOI: 10.3389/fimmu.2022.972930.


Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Roth K, Wenzel E, Ruschig M, Steinke S, Langreder N, Heine P Front Cell Infect Microbiol. 2021; 11:697876.

PMID: 34307196 PMC: 8294040. DOI: 10.3389/fcimb.2021.697876.


References
1.
Merrigan M, Venugopal A, Roxas J, Anwar F, Mallozzi M, Roxas B . Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile. PLoS One. 2013; 8(11):e78404. PMC: 3827033. DOI: 10.1371/journal.pone.0078404. View

2.
Cavalli-Bjorkman N, Osby E, Lundin J, Kalin M, Osterborg A, Gruber A . Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia. Med Oncol. 2003; 19(4):277-80. DOI: 10.1385/MO:19:4:277. View

3.
Calabi E, Calabi F, Phillips A, Fairweather N . Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun. 2002; 70(10):5770-8. PMC: 128314. DOI: 10.1128/IAI.70.10.5770-5778.2002. View

4.
de la Riva L, Willing S, Tate E, Fairweather N . Roles of cysteine proteases Cwp84 and Cwp13 in biogenesis of the cell wall of Clostridium difficile. J Bacteriol. 2011; 193(13):3276-85. PMC: 3133288. DOI: 10.1128/JB.00248-11. View

5.
Grandi G . Bacterial surface proteins and vaccines. F1000 Biol Rep. 2010; 2. PMC: 2950030. DOI: 10.3410/B2-36. View